Patents by Inventor Christian Barnett

Christian Barnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11026885
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 8, 2021
    Assignee: EYEPOINT PHARMACEUTICAS, INC.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Patent number: 9980911
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 29, 2018
    Assignee: PSIVIDA US, INC.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 9808421
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 7, 2017
    Assignee: PSIVIDA US, INC.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Patent number: 9603801
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 28, 2017
    Assignee: pSivida US, Inc.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20170049703
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: April 29, 2016
    Publication date: February 23, 2017
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20170035690
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20160243276
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 25, 2016
    Inventors: Paul ASHTON, Leigh T. Canham, Christian Barnett
  • Patent number: 9333173
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 10, 2016
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20140309610
    Abstract: This application provides a device for delivering a beneficial substance to a patient. The device comprises a shell enclosing a plurality of carrier particles. The carrier particles are porous, and a beneficial substance, such as a drug, is disposed in the pores. The drug can diffuse out of the pores, into the interior of the device, and then through at least one permeable portion of the shell. This application also provides methods of making and using these devices.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Applicant: pSivida Corp.
    Inventors: Leigh T. Canham, Hong Guo, Martin Nazzaro, Christian Barnett
  • Publication number: 20140271886
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: pSivida Corp
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20120177695
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: November 1, 2011
    Publication date: July 12, 2012
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett